IR-News

AUSSENDER



Medigene AG
Ansprechpartner: Medigene PR/IR
Tel.: +49 89 2000 33 3301
E-Mail: investor@medigene.com
pta20190211006
Business news for the stock market

Medigene AG: Medigene appoints Axel-Sven Malkomes as CFO/CBDO


Martinsried/Munich (pta006/11.02.2019/07:30) - Medigene AG (FWB: MDG1, Prime Standard, SDAX) a clinical stage immuno-oncology company focusing on the development of T-cell immunotherapies for the treatment of cancer, today announced that its Supervisory Board has appointed Axel-Sven Malkomes as Chief Financial Officer (CFO) and Chief Business Development Officer (CBDO) effective 1 April 2019. As a member of the Executive Management, Mr. Malkomes will be working at the Munich headquarters of Medigene and will assume responsibility for Finance, Business Development, Public & Investor Relations, Legal Affairs, IT and Commercial Operations.

Prof. Dr. Horst Domdey, Chairman of the Supervisory Board of Medigene: "Axel-Sven Malkomes brings to Medigene deep financial expertise combined with many years of management experience on the corporate, banking and investor sides in the fields of pharma and biotechnology. We are very pleased to gain such a qualified leader for the key corporate responsibilities of finance and business development who will further strengthen Medigene's current management team."

Axel-Sven Malkomes has been active in the healthcare sector for more than 25 years. Most recently, he has been Managing Director of the Life Sciences Practice for the British bank Barclays in Europe. Previously, he served as Global Head of Healthcare & Chemicals Investment Banking at the French corporate and investment bank Société Générale. On the investor side, Mr. Malkomes has accumulated relevant experience during his several years with the UK private equity firm 3i as co-head of European Healthcare Investments. Previously, he had leading operational and corporate roles at the German pharmaceutical company Merck KGaA, i.e. as CEO of a Merck KGaA group company and as Head of Strategic Planning as well as Mergers & Acquisitions/Business Development, where he significantly participated in the initial set-up and build-out of the company's oncology business. During his international management career, the graduate in business administration gained extensive knowledge of the pharmaceutical industry and medical sciences through his professional activities and comprehensive further education.

Axel-Sven Malkomes, designated CFO/CBDO of Medigene, comments: "Medigene is one of the highly exciting, promising biotechnology companies in the field of immuno-oncology. I am impressed with the great expertise of the team at Medigene and I am delighted with the opportunity to contribute to a successful future of the company. Together with my colleagues and the whole team, I am pleased to bring my experience to successfully help in the development of their cutting-edge cancer therapies."

Prof. Dr. Dolores Schendel, CEO of Medigene, adds: "On behalf of the management team, I welcome Axel-Sven as a new member of the Executive Management Board. He nicely complements our team with his broad knowledge and experience and will help Medigene to reach the next level of development. We look very much forward to working with him. "

Medigene AG (FSE: MDG1, ISIN DE000A1X3W00, Prime Standard, SDAX) is a publicly listed biotechnology company headquartered in Martinsried near Munich, Germany. The company is developing highly innovative immunotherapies to target various forms and stages of cancer. Medigene concentrates on the development of personalized T cell-based therapies with the fo-cus on T cell-receptor modified T cells (TCR-Ts) and has associated projects currently in pre-clinical and clinical development. For more information, please visit http://medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Contact Medigene AG
Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01,
email: investor@medigene.com

In case you no longer wish to receive any information about Medigene, please inform us by e-mail (investor@medigene.com). We will then delete your address from our distribution list.

(end)
emitter: Medigene AG
Lochhamer Straße 11
82152 Planegg
Germany
contact person: Medigene PR/IR
phone: +49 89 2000 33 3301
e-mail: investor@medigene.com
website: www.medigene.de
stock exchanges: regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Hannover, free market in Munich, free market in Stuttgart; open market in Berlin, Tradegate
ISIN(s): DE000A1X3W00
|
|
98.208 Abonnenten
|
174.277 Meldungen
|
70.369 Pressefotos

BUSINESS

21.09.2019 - 16:15 | dialog-Mail e-Mail Marketing Systems GmbH
21.09.2019 - 16:10 | OMF Online-Marketing-Forum.at GmbH
20.09.2019 - 14:30 | 2M Brandschutz
20.09.2019 - 14:15 | Photovoltaic Austria Bundesverband
20.09.2019 - 11:30 | Martschin & Partner GmbH
Top